FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

Congress Likely to Clarify Contrast Agent Dilemma: Attorney

Epstein Becker & Green attorney James Boiani believes Congress will step in to clarify that contrast agents should be regulated as drugs in the wake o...

Human Drugs

FDA Mulls Enforcement Discretion on NAC Products

FDA says that it is considering exercising enforcement discretion for N-acetyl-L-cysteine-containing products labeled as dietary supplements.

Medical Devices

FDA Approves Knee Cartilage Repair Implant

FDA approves a CartiHeal PMA for its Agili-C implant, indicated for treating an International Cartilage Repair Society (ICRS) Grade III or above knee-...

Human Drugs

FDA Wants to Change Generic Drug Exclusivity: Attorney

Attorney Kurt Karst says an FDA proposal to change the way generic drug exclusivity is awarded will result in fewer generic drugs coming to market.

Human Drugs

PQ/CMC Information Electronic Submission Project

FDA describes progress to date on its project to identify and prioritize pharmaceutical quality/chemistry, manufacturing, and controls (PQ/CMC) inform...

Medical Devices

FDA OKs Edwards Mitral Heart Valve

FDA approves Edwards Lifesciences Mitris Resilia valve, a tissue valve replacement specifically designed for the hearts mitral position.

Medical Devices

Magellan Resumes LeadCare II Distribution

FDA says Magellan Diagnostics is again distributing its LeadCare II blood test that had been part of a 2021 recall for a significant risk of falsely l...

Biologics

FDA Updates Covid Vaccine EUA Guidance

FDA updates its guidance on materials to be submitted to support the issuance of an emergency use authorization for a Covid-19 vaccine.

Human Drugs

Inspections Prioritized to Find Compliance/Data Integrity Issues

ORA Office of Pharmaceutical Quality Operations director Alonza Cruse says FDA is prioritizing inspections of firms with the highest risk of finding c...

Human Drugs

Lupin Says 13 Observations in Novel Labs Inspection

Lupin Pharmaceuticals says an FDA inspection at its Novel Laboratories subsidiary closed with 13 inspection observations.